ANGPTL3 and myocardial infarction: In broader populations, three lines of evidence—pedigrees, heterozygous deficiency in the general population, and plasma-level stratification in myocardial infarction case–control studies—converge on a protective effect: heterozygous ANGPTL3 LoF carriers had 34% lower CAD risk.